Review of once-monthly oral ibandronate and the use thereof

T De Villiers
M Davey
B Cassim
W De Lange

Keywords: ibandronate, oral, use, once-monthly

Abstract

An advisory board meeting of key opinion leaders was held in 2015 to discuss the clinical data on oral ibandronate in the treatment of postmenopausal osteoporosis. Boniva 150 mg (ibandronate) oral once-monthly is indicated for the treatment of osteoporosis in postmenopausal women, in order to reduce the risk of vertebral fractures.¹

Author Biographies

T De Villiers

Chairman Ibandronate Oral Advisory Group

M Davey

Ibandronate Oral Advisory Group

B Cassim

Ibandronate Oral Advisory Group

W De Lange

Ibandronate Oral Advisory Group

Published

2017-05-05

Issue

Vol 22 No 1 (2017)

Section

Consensus Document

Material submitted for publication in the Journal of Endocrinology, Metabolism and Diabetes of South Africa (JEMDSA) is accepted provided it has not been published elsewhere. JEMDSA reserves copyright of the material published. Neither JEMDSA nor the Publisher may be held responsible for statements made by the authors.